Pfizer Inc
NYSE: PFE
$29.27
-$0.40 (-1.3%)
Closing Price on October 17, 2024
PFE Articles
As of the most recently reported period, short sellers still favored Pfizer, Intel and Microsoft above all other Dow stocks.
Published:
Last Updated:
Of the 40 worst performers in the S&P 500 so far in 2019, 11 are tied to oil and gas, 10 tied mostly to retailing of apparel and accessories, and six are tied to pharmaceuticals and biotech.
Published:
Last Updated:
GlycoMimetics shares were crushed on Monday after the firm announced late-stage results from its sickle cell disease trial in conjunction with Pfizer.
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen on Tuesday included Cisco Systems, Duke Energy, Goodyear, Illumina, Kinder Morgan, Micron Technology, Pfizer and Tencent Music.
Published:
Last Updated:
Pfizer and Merck are each scheduled to release their second-quarter financial results early Tuesday. These are just a couple of the Dow Jones industrials that are reporting this week, but they make...
Published:
Last Updated:
Mylan released its second-quarter financial results before the markets opened on Monday. The pharma giant also announced a major update to its business involving Pfizer and that CEO Heather Bresch is...
Published:
Last Updated:
Seven of the 30 Dow Jones industrial average components are scheduled to report their latest quarterly reports this week, including Apple, Exxon and Pfizer.
Published:
Last Updated:
The Dow Jones industrial average in an all-time high territory, and a lot of experts believe it has room to run. But one particular stock is not helping.
Published:
Last Updated:
The July 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
Published:
Last Updated:
As of the most recently reported period, short sellers favored Intel, Pfizer and Microsoft above all other Dow stocks.
Published:
Last Updated:
The June 28 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were increased.
Published:
Last Updated:
As of the most recently reported period, short sellers favored Pfizer, Intel and Microsoft above all other Dow stocks.
Published:
Last Updated:
Here are five solid defensive picks for investors in what is a very expensive market, and they are also under-owned by active fund managers. All are rated Buy at Merrill Lynch.
Published:
Last Updated:
President Trump lost ground with his efforts to force drug companies to list drug prices on TV ads, with the effort being blocked on free speech concerns.
Published:
Last Updated:
Sangamo Therapeutics made a handy gain to start out the week after the firm, in conjunction with Pfizer, announced updated results from a mid-stage trial evaluating a treatment for hemophilia.
Published:
Last Updated: